Giuseppe Accogli became the Group CEO of Chiesi Pharmaceuticals in 2023. With a 25-year career in the med-tech industry, he ...

I envision Chiesi as a proactive leader driving innovation and collaboration within the rare disease community. Our goal is ...

Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.

Seven hotels in the UK earned themselves B Corp status between 2021 and 2024. Emma Henderson investigates what this actually means for an intrinsically energy-intensive industry – and whether the stat ...

Pulmonary Or Respiratory Drug Delivery Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 The Business Research ...

Minoryx Therapeutics, a late-stage biotech company focused on the development of therapies for orphan central nervous system (CNS) disorders, today announces that the first patient in the TREE study ...

Over the 5 years following a single steroid injection, prescriptions for opioid-nonopioid combination products (e.g., ...

XOMA Royalty ( NASDAQ:XOMA ) Third Quarter 2024 Results Key Financial Results Revenue: US$7.20m (up by US$6.37m from 3Q... EMERYVILLE, Calif. AP) — XOMA Royalty Corporation (XOMA) on Thursday ...